HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Stranded Biotech Asset Intelligence

Explore Opportunities

Find → Filter → Understand → Compare → Watch → Resolve. Discovery priority is not acquisition readiness.

1067 matching exact-name labels; not unique global drugs.

Select 2–10 for a subscription comparison.

UNKNOWN · LOW discovery confidence

Silver nitrate + triamcinolone

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Silver nitrate + triamcinolone in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Simvastatin

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: strategic reprioritization. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Simvastatin in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Sinapis nigrea semen

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Sinapis nigrea semen in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Single agent zimberelimab

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Single agent zimberelimab in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Single dose of methadone

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: financing failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Single dose of methadone in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

sipuleucel-T

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for sipuleucel-T in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Sirolimus

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1 Source 2
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Sirolimus in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

sirolimus and ATRA

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for sirolimus and ATRA in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Sitagliptin

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Sitagliptin in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Sitz-Markers

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Sitz-Markers in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

SN514-066b

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for SN514-066b in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

SNG001

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for SNG001 in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →